November 11-12 | In-Person & Digital (London) 

GLOBAL PHARMA AND BIOTECH SUMMIT

Strategic intelligence driving biopharma's next chapter

The biopharma industry is entering uncharted territory. AI is transforming drug discovery at unprecedented speed, while breakthroughs in precision medicine and obesity treatments are fundamentally changing patient care.

Innovation alone won't guarantee success. Regulatory fragmentation, geopolitical tensions, and strained health systems are testing even the strongest players. At the Global Pharma and Biotech Summit, C-suite executives, pioneering scientists and leading investors will deliver sharp insights on what’s working in biopharma — from discovery to delivery.

Keynote interviews

Topics include:

• Mega-deals are out, and more focused partnerships and licensing transactions are in — what does it mean for the capital return cycle?
• Pharma companies face growing divergence in regulation and health policy between key markets — how can we harmonize?
• China’s transformation into a biopharma innovation powerhouse is prompting strategic recalibration across the industry — what's next?

Whether you join us in person or virtually, you'll gain the strategic intelligence needed to turn disruption into competitive advantage.

Kick off the two-day event with a fast-paced news brief featuring Endpoints News Executive Editor Drew Armstrong and Financial Times Global Pharmaceutical Editor Hannah Kuchler. Reporters from Endpoints and the FT will interview industry leaders and moderate in-depth panel discussions on the trends shaping the future of life sciences.